TrialPath

Find a study

Match me to a study

83 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

73 studies on the map

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder — University of Alabama - Huntsville Regional Medical Campus /ID# 267818, HuntsvilleA Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) — Local Institution - 0106, PhoenixStudy of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V — AKDHC Medical Research ServicesLLC, PhoenixStudy of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder — Clinical Site, BirminghamThe Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study — University of California, San Francisco, San FranciscoStudy of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder — Clinical Site, ChandlerA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) — GSK Investigational Site, AnnistonRESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus — University of California Irvine, OrangeA Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE) — Wallace & Lee Center, Beverly HillsRE104 Safety and Efficacy Study in Generalized Anxiety Disorder — Lighthouse Psychiatry, GilbertA Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN) — University Of Alabama, BirminghamA Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) — Nkarta Investigational Site, Little RockA Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE — Research Site, San FranciscoVIBRANT: VIB4920 for Active Lupus Nephritis — University of California San Diego School of Medicine: Division of Rheumatology, Allergy and Immunology, La JollaA Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases — HonorHealth Research and Innovation Institute, ScottsdaleA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants — Loma Linda University health, Loma LindaA Study of Obexelimab in Patients With Systemic Lupus Erythematosus — Sierra Pacific Arthritis and Rheumatology Centers, FresnoA Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder — Vistagen Clinical Site, Sherman OaksPRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis — Purushotham & Akther Kotha MD, Inc., La MesaA Study of NTX-1472 in Social Anxiety Disorder — SOAR Clinical Study Site, EncinoA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus — Investigative Site, Beverly HillsSafety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial — AARA Clinical Research, GlendaleA Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants — US06-0, La PalmaA Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132 — Local Institution - 0001, FarmingtonObe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN) — State University of New York Upstate Medical Center (SUNY), SyracuseStudy of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders — National Institutes of Health Clinical Center, BethesdaModulating Exercise Dosage to Improve Concussion Recovery — University of Colorado Denver, AuroraIMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy — Hospital for Special Surgery, New YorkPramipexole to Enhance Social Connections — University of California, San Diego, San DiegoSearch for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness — Acacia Clinics, SunnyvaleSleep, Dreaming, and Virtual Reality for Mental Health — Northwestern University, EvanstonDescartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders — H01- Children's National Hospital, Washington D.C.Safety of the Herpes Zoster Subunit Vaccine in Lupus — NYU Langone Health, New YorkPhase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders — MD Anderson Cancer Center, HoustonDapagliflozin in Active Lupus Nephritis — Massachusetts General Hospital, BostonAcceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesTRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors — The University of Texas M. D. Anderson Cancer Center, HoustonNeuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV — Massachusetts General Hospital, BostonFamily Acceptance Project Online (Pilot RCT) — University of Michigan, Ann ArborCombination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer — MD Anderson Cancer Center, HoustonCannabis for Palliative Care in Cancer — Anschutz Health Sciences Building, AuroraProcesses and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression — Laureate Institute for Brain Research, TulsaA New Intervention to Improve Function in Veterans With Anxiety and Depression — Durham VA Medical Center, Durham, NC, DurhamAcute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A) — University of Cincinnati, CincinnatiGroup Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies — Fred Hutch/University of Washington Cancer Consortium, SeattlePharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation — Mclean Hospital, BelmontCannabidiol and Older Adult Cannabis Users — University of Colorado at Boulder, BoulderPsilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy — MD Anderson Cancer Center, HoustonPromoting Active Therapy: Path to Wellness — Kansas State University, ManhattanLeveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City — Washington University School of Medicine, St LouisPersonalized Brain Stimulation to Treat Chronic Concussive Symptoms — UCLA, Westwood, Los AngelesUse of CBD in the Treatment of Anxiety — University of Florida, GainesvilleEfficacy and Safety of Magnesium Vitamin B6 in First Episode Bipolar Disorder — McLean Hospital, BelmontEnhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) — UC San Diego, San DiegoPsilocybin-Assisted Therapy for Intergenerational Trauma — The Parsons Research Center for Psychedelic Healing, New YorkTrial of Belimumab in Early Lupus — Feinstein Institute, ManhassetPharmacogenetically-guided Escitalopram Treatment for Pediatric Anxiety: Aiming to Improve Safety and Efficacy (PrEcISE) — University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, CincinnatiFeasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer — Cedars-Sinai Medical Center, Los AngelesGaze-Contingent Music Therapy Augmentation of CBT for Pediatric Anxiety — National Institutes of Health Clinical Center, BethesdaInvestigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults — Southwest Autism Research and Resource Center, PhoenixStudy of Dextromethorphan in OCD and Related Disorders — Stanford University, StanfordTrial With the Treatment of Sertraline in Youth With Generalized, Separation and/or Social Anxiety Disorders. — University of Cincinnati, CincinnatiEvaluating Buspirone to Treat Opioid Withdrawal — Kahlert Institute for Addictino Medicin, BaltimoreCannabidiol Effects on Learning and Anxiety — University of Connecticut, StorrsSelf-Adjusted Nitrous Oxide: A Feasibility Study in the Setting of Vasectomy — Beth Israel Deaconess Medical Center, BostonDouble-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus — National Institutes of Health Clinical Center, BethesdaAutologous Stem Cell Transplant (ASCT) for Autoimmune Diseases — Children's Hospital of Philadelphia, PhiladelphiaEarly Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor — Lucile Packard Children's Hospital, Palo AltoCD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus — Children's Hospital of Philadelphia, PhiladelphiaSafety and Efficacy of ONT01 in Lupus — Hospital for Special Surgery, New YorkThe Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD — National Institutes of Health Clinical Center, Bethesda2-HOBA in Systemic Lupus Erythematosus — Vanderbilt University Medical Center, NashvilleProspective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users — Research Site, Las Vegas